Alogliptin was first approved by the FDA in January 2013 as a therapy to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). It is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in conjunction with diet and exercise. This activity outlines the indications, mechanism, pharmacology, contraindications, and adverse events associated with alogliptin drug therapy.

**Objectives:**
- Identify the mechanism of action of alogliptin.
- Describe the possible adverse effects of alogliptin, including necessary dose adjustments to address them where indicated.
- Summarize the pharmacology of alogliptin.
- Outline the importance of collaboration and coordination among the interprofessional team and how it can enhance patient care when dosing alogliptin to improve patient outcomes for patients requiring glycemic control.